UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised T cell therapy for lung and ski
With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. There is a crucial need to progress candidates from bench to bedside.
Fresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in second-round financing led by venture capital groups Arix Bioscience and RTW In
US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that affects the eye into late-sta